NexImmune, Inc.
NEXI
$0.00
$0.000.00%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.30% | -45.60% | -34.98% | 7.26% | -28.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -64.93% | -71.93% | -90.86% | -32.72% | -51.12% |
| Operating Income | 64.93% | 71.93% | 90.86% | 32.72% | 51.12% |
| Income Before Tax | 69.25% | 67.83% | 68.28% | 33.10% | 52.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 69.25% | 67.83% | 68.28% | 33.10% | 52.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 69.25% | 67.83% | 68.28% | 33.10% | 52.29% |
| EBIT | 64.93% | 71.93% | 90.86% | 32.72% | 51.12% |
| EBITDA | 64.69% | 72.36% | 92.06% | 33.33% | 52.07% |
| EPS Basic | 76.76% | 73.16% | 68.87% | 37.66% | 58.16% |
| Normalized Basic EPS | 84.55% | 72.29% | 91.47% | 37.66% | 58.16% |
| EPS Diluted | 76.76% | 73.16% | 68.87% | 37.66% | 58.16% |
| Normalized Diluted EPS | 84.55% | 72.29% | 91.47% | 37.66% | 58.16% |
| Average Basic Shares Outstanding | 32.34% | 19.88% | 1.89% | 7.32% | 14.01% |
| Average Diluted Shares Outstanding | 32.34% | 19.88% | 1.89% | 7.32% | 14.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |